AQR Capital Management
MAZE

AQR Capital Management’s Maze Therapeutics MAZE Stock Holding History

AQR Capital Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$834K Buy
27,945
+506
+2% +$22.3K ﹤0.01% 2870
2025
Q4 		$1.14M Sell
27,439
-176
-0.6% -$6.05K ﹤0.01% 2476
2025
Q3 		$716K Buy
27,615
+148
+0.5% +$2.5K ﹤0.01% 2622
2025
Q2 		$337K Buy
+27,467
New +$286K ﹤0.01% 2804

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management's MAZE Position: Q1 2026 in Review

AQR Capital Management increased its Maze Therapeutics (MAZE) stake by 1.8% in Q1 2026, buying an estimated $22.3K and bringing the position to 27,945 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #2870.

AQR Capital Management first reported a position in MAZE in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.14M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • AQR Capital Management held 27,945 shares of Maze Therapeutics worth $834K as of Q1 2026.
  • AQR Capital Management bought 506 Maze Therapeutics shares in Q1 2026, an estimated $22.3K.
  • Maze Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2870 holding.
  • AQR Capital Management first reported a position in Maze Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • AQR Capital Management's Maze Therapeutics position peaked at $1.14M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.